Smiths Medical takes on head of North America
This article was originally published in Clinica
Executive Summary
Stuart Morris-Hipkins has been named as president of the North America division of Smiths Medical (London, UK). Based at its Massachusetts office, Mr Morris-Hipkins will be responsible for all sales, R&D, marketing and customer service for all product lines in the US and Canada. He joined the firm in 1998 and was most recently president of vital care and safety businesses. His appointment is part of an operations restructuring. He has 15 years’ experience in the field, and during his time at Smiths has “led a variety of strategic growth, acquisition, restructuring, continuous improvement and outsourcing projects across three continents". Company president Srini Seshadri described his track record of delivering growth and raising business performance levels as “impressive.” Smiths Medical designs, develops and manufactures a number of devices in three core areas: safety devices; vital care and medication delivery.
You may also be interested in...
Asia Regulatory Forum Update
Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.
Saudi Arabia adopts interim device authorisation regulation
Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.
Canada takes action to increase more adverse event reporting
The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.